Table 1 Baseline patient characteristics
pAT (N = 112) | AT gamma (N = 110) | ||
|---|---|---|---|
Sex | Female | 51 (45.5) | 51 (46.4) |
Male | 61 (54.5) | 59 (53.6) | |
Age, years | Mean ± SD | 71.0 ± 15.5 | 70.4 ± 15.2 |
< 65 | 24 (21.4) | 34 (30.9) | |
65 to < 75 | 34 (30.4) | 20 (18.2) | |
75 to < 85 | 36 (32.1) | 41 (37.3) | |
≥ 85 | 18 (16.1) | 15 (13.6) | |
Body weight, kg | Mean ± SD | 54.3 ± 12.3 | 53.8 ± 14.0 |
< 55 | 57 (50.9) | 63 (57.3) | |
≥ 55 | 55 (49.1) | 47 (42.7) | |
Bleeding symptoms at baseline | Absent | 90 (80.4) | 93 (84.5) |
Present | 22 (19.6) | 17 (15.5) | |
DIC score at enrollment | Mean ± SD | 5.6 ± 1.4 | 5.6 ± 1.2 |
< 6 | 60 (53.6) | 62 (56.4) | |
≥ 6 | 52 (46.4) | 47 (42.7) | |
SOFA score at enrollment | Mean ± SD | 8.9 ± 3.7 | 9.1 ± 3.3 |
< 10 | 64 (57.1) | 58 (52.7) | |
≥ 10 | 47 (42.0) | 50 (45.5) | |
APACHE II score at enrollment | Mean ± SD | 18.8 ± 6.8 | 18.2 ± 6.5 |
< 20 | 68 (60.7) | 61 (55.5) | |
≥ 20 | 41 (36.6) | 47 (42.7) | |
AT activity (%) at enrollment (on-site measurement) | Mean ± SD | 50.9 ± 12.3 | 51.5 ± 11.6 |
< 50 | 43 (38.4) | 41 (37.3) | |
50 to ≤ 70 | 69 (61.6) | 68 (61.8) | |
Anticoagulant therapy use | Gabexate mesylate | 22 (19.6) | 21 (19.1) |
Nafamostat mesylate | 6 (5.4) | 4 (3.6) | |
Thrombomodulin | 35 (31.3) | 34 (30.9) | |
Heparins | 31 (27.7) | 32 (29.1) | |
Replacement therapy use | Fresh frozen plasma | 24 (21.4) | 10 (9.1) |
Platelet concentrate | 26 (23.2) | 22 (20.0) | |
Any anticoagulant use | 83 (74.1) | 76 (69.1) | |